The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU® (Trastuzumab Deruxtecan, T-DXd) versus physician’s choice of chemotherapy in hormone receptor-positive metastatic breast cancer patients. Study Overview: Dr. Aditya Bardia presented the findings from DESTINY-Breast06, a Phase 3 trial that included patients with HER2-low and … Continue reading ENHERTU® (Trastuzumab Deruxtecan, T-DXd) Outperforms Chemotherapy in Metastatic Breast Cancer: SABCS 2024 DESTINY-Breast06 Results